Abstract
Mitochondria are involved in different physiological and pathological processes that are crucial for tumor cell physiology, growth and survival. Since cancer cells have frequently disrupted different cell death pathways that promote their survival, mitochondria may be key organelles to promote cell death in cancer cells. The present review is focused on the different experimental and therapeutic cancer strategies addressed to either target mitochondria directly, or use mitochondria as mediators of apoptosis. While the first group includes drugs that act on glycolysis, β-oxidation, electron transport chain, mitochondrial permeability and the Bcl-2/IAP family protein, the second one consists of those drugs that cause cell death through the intrinsic apoptosis pathway by promoting ROS generation or by modulating mitochondrial protein involved in apoptosis induction.
Keywords: Apoptosis, metabolism, oxidative stress, therapy, anti-tumoral therapy, cardiolipin, DNA fragmentation, Vitamin E, caspases, glycolysis
Current Pharmaceutical Design
Title: Mitochondrial Drug Targets in Cell Death and Cancer
Volume: 17 Issue: 20
Author(s): Gustavo Ferrin, Clara I. Linares and Jordi Muntane
Affiliation:
Keywords: Apoptosis, metabolism, oxidative stress, therapy, anti-tumoral therapy, cardiolipin, DNA fragmentation, Vitamin E, caspases, glycolysis
Abstract: Mitochondria are involved in different physiological and pathological processes that are crucial for tumor cell physiology, growth and survival. Since cancer cells have frequently disrupted different cell death pathways that promote their survival, mitochondria may be key organelles to promote cell death in cancer cells. The present review is focused on the different experimental and therapeutic cancer strategies addressed to either target mitochondria directly, or use mitochondria as mediators of apoptosis. While the first group includes drugs that act on glycolysis, β-oxidation, electron transport chain, mitochondrial permeability and the Bcl-2/IAP family protein, the second one consists of those drugs that cause cell death through the intrinsic apoptosis pathway by promoting ROS generation or by modulating mitochondrial protein involved in apoptosis induction.
Export Options
About this article
Cite this article as:
Ferrin Gustavo, I. Linares Clara and Muntane Jordi, Mitochondrial Drug Targets in Cell Death and Cancer, Current Pharmaceutical Design 2011; 17 (20) . https://dx.doi.org/10.2174/138161211796904803
DOI https://dx.doi.org/10.2174/138161211796904803 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
UBE2L6 is Involved in Cisplatin Resistance by Regulating the Transcription of ABCB6
Anti-Cancer Agents in Medicinal Chemistry Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Recent Patents on Morphometric Analysis of Eukaryotic Cells
Recent Patents on Medical Imaging Mitochondrial-Targeted Plastoquinone Derivatives. Effect on Senescence and Acute Age-Related Pathologies
Current Drug Targets Current Progress of Reelin in Development, Inflammation and Tissue Remodeling: From Nervous to Visual Systems
Current Molecular Medicine Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy
Current Drug Therapy Pharmacological Potentials and Nutritional Values of Tropical and Subtropical Fruits of India: Emphasis on their Anticancer Bioactive Components
Recent Patents on Anti-Cancer Drug Discovery Magnetic Resonance Imaging of the Cervix, and its Relevance to the Revised International Federation of Gynecology and Obstetrics (FIGO) Staging
Current Medical Imaging Positron Emission Tomography Imaging of Tumor Hypoxia
Current Medical Imaging Neonatal Germ Cell Tumors
Current Pediatric Reviews Diagnostic and Therapeutic Use of Human Recombinant Thyrotropin (rhTSH)(Thyrogen®) in Well-Differentiated Thyroid Cancer - Current Indications and Future Perspectives - A Review
Current Pharmaceutical Analysis Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Current Perspectives on Cytokines for Anti-retroviral Therapy in AIDS Related B-cell Lymphomas
Current Drug Targets - Infectious Disorders In Vitro Cytotoxic Activities of Platinum(II) Complex with 1-Methyl-2-(3'- hydroxypropyl)benzimidazole and 2-(3'-Hydroxypropyl)benzimidazolium Hexa- and Tetrachloroplatinate Salts
Letters in Drug Design & Discovery Transdermal Delivery of 5-Fluorouracil for Induced Ehrlich Ascites Carcinoma Tumor in Balb/c Mice and Pharmacokinetic Study
Recent Patents on Anti-Cancer Drug Discovery Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design